radium and docetaxel anhydrous
radium has been researched along with docetaxel anhydrous in 46 studies
Research
Studies (46)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 36 (78.26) | 24.3611 |
2020's | 10 (21.74) | 2.80 |
Authors
Authors | Studies |
---|---|
Beuzeboc, P; Goldwasser, F; Ropert, S; Zerbib, M | 1 |
Blom, R; Bolstad, B; Bruland, ØS; Franzén, L; Johannessen, DC; Lennernäs, B; Nilsson, S; O'Bryan-Tear, CG; Parker, C; Petersson, U; Pigott, K; Sokal, M; Tennvall, J; Thuresson, M; Tyrrell, C | 1 |
Lewis, B; Pal, SK; Sartor, O | 1 |
Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
D'Amico, AV | 1 |
Bahl, A | 1 |
Gurney, H; Parente, P; Parnis, F | 1 |
Den, RB; Kelly, WK | 1 |
Aksnes, AK; Bottomley, D; Fang, F; Helle, SI; Hoskin, P; Johannessen, DC; Logue, J; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Vogelzang, NJ; Wahba, M | 1 |
Nilsson, S | 1 |
Chopra, S; Rashid, P | 1 |
Attard, G; de Bono, JS; Lorente, D; Mateo, J; Perez-Lopez, R | 1 |
Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
Dreicer, R | 1 |
Armstrong, AJ; Li, J | 1 |
Chowdhury, S; Gilson, C; Kirby, R; Manickavasagar, T | 1 |
Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
Cislo, P; Coleman, RE; Nilsson, S; O'Sullivan, JM; Parker, C; Reuning-Scherer, J; Sartor, O; Shan, M; Vogelzang, NJ; Zhan, L | 1 |
Coleman, RE; Hoskin, P; Nilsson, S; Parker, C; Petrenciuc, O; Sartor, O; Staudacher, K; Thuresson, M; Vogelzang, NJ | 1 |
Balk, M; Bui, CN; Flanders, S; Francis, P; O'Day, K; Oestreicher, N; Popelar, B; Posta, L; Tang, H | 1 |
Ackermann, CJ; Gillessen, S; Hager, S; Joerger, M; Omlin, A | 1 |
Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S | 1 |
Bolton, D; Corfield, J; Crozier, J; Joshua, AM; Lawrentschuk, N | 1 |
Aitoku, Y; Basurto, E; Concialdi, K; DiBonaventura, M; Kimura, G; Ledesma, DA; Matsubara, N; McKinnon, I; Mohamed, AF; Narimatsu, A; Uemura, H; Wang, E; Yamaguchi, A | 1 |
Armstrong, A; Balk, M; Brown, B; Bui, C; Chambers, J; Deangelis, J; Fitch, K; Flanders, S; Sawhney, TG | 1 |
Baldari, S; Boni, G; Bortolus, R; Caffo, O; Conti, G; De Vincentis, G; Monari, F; Procopio, G; Santini, D; Seregni, E; Valdagni, R | 1 |
Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A | 1 |
Hinz, S | 1 |
Cicero, G; Costa, RP; De Luca, R; Murabito, A; Tripoli, V | 1 |
Heidenreich, A; Nilsson, S; Parker, C; Shore, N | 1 |
Gillessen, S; Isensee, G; Müller, J; Omlin, A; Péporté, A; Schmid, S | 1 |
Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 1 |
Dondossola, E; Friedl, P; Logothetis, CJ; Navone, N; Paindelli, C | 1 |
Buonerba, C; Di Lorenzo, G; Fizazi, K; Pagliuca, M | 1 |
Antonarakis, ES; Carrasquillo, JA; Deandreis, D; Fizazi, K; Higano, CS; Jacene, HA; Loriot, Y; Lu, C; Morris, MJ; Pandit-Taskar, N; Petrenciuc, O; Ryan, CJ; Shevrin, DH; Sweeney, CJ; Vesselle, H | 1 |
Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W | 1 |
Casadei, C; Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D; Stellato, M; Tonini, G | 1 |
Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D | 1 |
Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK | 1 |
Aben, KKH; Bergman, AM; Coenen, JLLM; de Wit, R; Gerritsen, WR; Kuppen, MCP; Mehra, N; Somford, DM; Uyl-de Groot, CA; van den Bergh, ACM; van den Eertwegh, AJM; van Moorselaar, RJA; van Oort, IM; Westgeest, HM | 1 |
Alongi, F; Alongi, P; Baldari, S; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; Costa, RP; De Giorgi, U; De Vincentis, G; Donner, D; Facchini, G; Fanti, S; Frantellizzi, V; Galli, L; Lo Re, G; Masini, C; Monari, F; Morabito, A; Pignata, S; Pinto, C; Salgarello, M; Sbrana, A; Spada, M; Tucci, M; Zichi, C | 1 |
Biggart, S; Cole, A; Grey, A; Hounsell, AR; Jain, S; McGarry, CK; Mitchell, D; O'Sullivan, JM; Prise, KM; Turner, PG | 1 |
Kamoto, T; Kimura, T; Mukai, S; Nagano, M; Okabe, KO; Onizuka, C; Otuka, I; Shirakawa, T; Takamori, H; Terada, N; Ueno, T; Yamashita, Y | 1 |
Chen, CH; Chen, IA; Chen, YH; Chen, YT; Cheng, YT; Chiang, PC; Chiang, PH; Kang, CH; Liu, YY; Luo, HL; Su, YL; Wang, HJ | 1 |
Abramowitz, E; O'Sullivan, JM; Sierra-Scacalossi, L | 1 |
Reviews
21 review(s) available for radium and docetaxel anhydrous
Article | Year |
---|---|
[Management of metastatic castration-resistant prostate cancer following docetaxel].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Treatment Failure | 2012 |
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Failure | 2012 |
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2013 |
Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2014 |
Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Australia; Disease Progression; Docetaxel; General Practice; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2015 |
Sequencing of agents in castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts; Treatment Outcome | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.
Topics: Androgen Receptor Antagonists; Benzamides; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Platinum Compounds; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2016 |
Understanding the role of new systemic agents in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2016 |
Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Topics: Bone Neoplasms; Disease Management; Docetaxel; Humans; Italy; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Treatment Outcome | 2017 |
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
[Monitoring of treatment for metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Outcome and Process Assessment, Health Care; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
Current approaches to incorporation of radium-223 in clinical practice.
Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome | 2018 |
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Retrospective Studies; Taxoids; Thiohydantoins; Tissue Extracts | 2019 |
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Tumor Microenvironment | 2020 |
Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2020 |
Contemporary management of advanced prostate cancer: an evolving landscape.
Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational | 2021 |
Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan.
Topics: Alkaline Phosphatase; Docetaxel; Humans; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Taiwan; Treatment Outcome | 2023 |
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Trials
7 trial(s) available for radium and docetaxel anhydrous
Article | Year |
---|---|
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPC
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2014 |
Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Neoplasms; Bone Remodeling; Collagen Type I; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Staging; Peptides; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Standard of Care; Taxoids; Treatment Outcome | 2016 |
Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Placebos; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Radium; Treatment Outcome | 2021 |
Other Studies
18 other study(ies) available for radium and docetaxel anhydrous
Article | Year |
---|---|
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Pain Management; Palliative Care; Proportional Hazards Models; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |
Effect of docetaxel on safety and efficacy of radium-223.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2014 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Pain; Pain Measurement; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium; Taxoids | 2015 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2015 |
New developments in metastatic prostate cancer therapy.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Staging; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy; Radium; Risk Assessment; Taxoids; Therapies, Investigational; United Kingdom | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts | 2015 |
Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Budgets; Docetaxel; Drug Costs; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States | 2016 |
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abdominal Neoplasms; Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Topics: Aged; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Japan; Male; Patient Preference; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2016 |
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
Topics: Aged; Androstenes; Benzamides; Docetaxel; Drug Costs; Health Care Costs; Humans; Male; Medicare; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; United States | 2017 |
The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Italy; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Retrospective Studies; Taxoids | 2018 |
Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Denosumab; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radium; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Culture Techniques; Cell Proliferation; Docetaxel; Drug Screening Assays, Antitumor; Humans; Male; Mice, SCID; PC-3 Cells; Prostatic Neoplasms; Radium; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2019 |
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids | 2020 |
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemoradiotherapy; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2022 |